Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study - Scorecard - MDSpire

Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study

  • By

  • Zhiming Cai

  • Zhengnan Xu

  • Huimei Lin

  • Huibin Liu

  • Zihan Lin

  • Jinhu Chen

  • Shichai Hong

  • Weibin Song

  • Xinyu Chen

  • Yanchang Xu

  • Zhenrong Yang

  • Yongjian Zhou

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Risk Stratification Using Prognostic Inflammatory-Immune Scores Enhances Adjuvant Therapy for Non-Gastric Gastrointestinal Stromal Tumors: Findings from a Multicenter Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingMulticenter retrospective cohort study across five hospitals in China, with citation needed.

Key Highlights

  • Adjuvant therapy beyond 3 years improved recurrence-free survival in medium- and high-risk subgroups, needs citation.

Guideline-Based Recommendations

Diagnosis

    Management

    • Utilization of the Prognostic Inflammatory–Immune Score for risk stratification and adjuvant imatinib therapy duration, needs citation.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        471 patients with primary non-gastric GISTs.

        Adjuvant therapy duration should be tailored based on risk stratification from the PIIS.

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study

          • by Zhiming Cai, Zhengnan Xu, Huimei Lin, Huibin Liu, Zihan Lin, Jinhu Chen, Shichai Hong, Weibin Song, Xinyu Chen, Yanchang Xu, Zhenrong Yang, Yongjian Zhou

          • June 2, 2026

          Related Content

          Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis

          Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

          Treatment of parotid gland oncocytoma: a case report from a radiation oncologist’s perspective